FRIDAY, Might 6, 2022
Citing the gathered information on a raised threat for a sort of harmful blood clot, the U.S. Meals and Drug Administration on Thursday drastically restricted the advisable use of the Johnson & Johnson COVID-19 vaccine.
With safer two-dose vaccines comparable to Pfizer and Moderna extensively out there, the one-dose J&J shot must be restricted “to people 18 years of age and older for whom different approved or accepted COVID-19 vaccines usually are not accessible or clinically applicable,” the company stated in a press release.
It might even be utilized by “people 18 years of age and older who elect to obtain the Janssen COVID-19 Vaccine as a result of they might in any other case not obtain a COVID-19 vaccine [at all],” the FDA suggested.
Whereas the J&J vaccine has appealed to some as a result of it solely requires one-dose, information quickly emerged suggesting a better threat in customers of a uncommon type of blood clot generally known as thrombocytopenia syndrome (TTS).
In accordance to the FDA, TTS is “a syndrome of uncommon and probably life-threatening blood clots together with low ranges of blood platelets.”
Some individuals — usually younger males — sometimes developed signs a couple of week or two after getting the J&J shot. The information gathered on this threat now “warrants limiting the approved use of the vaccine,” the company stated.
Getting the J&J vaccine can nonetheless assist stop severe sickness with COVID-19, so the shot “nonetheless has a job within the present pandemic response in america and throughout the worldwide neighborhood,” Dr. Peter Marks, director of the FDA’s Middle for Biologics Analysis and Analysis, stated within the assertion.
However “our motion displays our up to date evaluation of the chance of TTS following administration of this vaccine,” he stated, “and limits using the vaccine to sure people.”
Marks added that “the company will proceed to monitor the protection of the Janssen [J&J] COVID-19 Vaccine and all different vaccines, and as has been the case all through the pandemic, will completely consider new security data.”
The vaccine first acquired an emergency use authorization in late February of 2021. However after six circumstances of TTS have been reported, the FDA positioned a short lived “pause” on use of the J&J shot because it gathered extra information.
That pause was lifted on April 23, 2021, when a complete of 15 circumstances of TTS have been reported from the greater than 8 million vaccine doses doled out throughout throughout america.
On the time, “the recognized and potential advantages of Janssen [J&J] COVID-19 Vaccine outweighed its recognized and potential dangers in people 18 years of age and older,” the FDA stated.
Nonetheless, by December, the company suggested that mRNA COVID vaccines (these made by Pfizer or Moderna) have been now most well-liked over the J&J shot.
Within the newest evaluation, the FDA famous that by March 18, 2022, “the FDA and CDC have recognized 60 confirmed circumstances, together with 9 deadly circumstances,” of TTS in individuals who’d acquired the J&J vaccine.
The danger nonetheless stays extraordinarily uncommon: About three circumstances for each 1 million doses of vaccine administered. It is stays unclear if any particular elements place a person at heightened threat for the blood clots after receiving the vaccine.
Whereas very uncommon, TTS can shortly show harmful, nevertheless. Sufferers “could quickly deteriorate, regardless of immediate prognosis and therapy,” the FDA stated, and the clots “can lead to long-term and debilitating well being penalties,” together with a excessive threat for demise.
So, the most recent advice is that the J&J vaccine be used solely by individuals who may need a severe allergic response to the Pfizer or Moderna vaccines, or those that (for no matter cause) don’t want to obtain an mRNA vaccine and who would subsequently in any other case stay unvaccinated.
Extra data
Discover out extra about COVID-19 vaccines on the U.S. Facilities for Illness Management and Prevention.
SOURCE: U.S. Meals and Drug administration, information launch, Might 5, 2022
By Robin Foster and Ernie Mundell HealthDay Reporters
Copyright © 2021 HealthDay. All rights reserved.
